CRISPR-Based Therapeutics - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510244535

Publication Date:

October 25, 2024

Pages:

106

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

CRISPR鈥恇ased genome editing technology has become an important potential therapeutic tool for various diseases.
The global market for CRISPR-Based Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for CRISPR-Based Therapeutics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CRISPR-Based Therapeutics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for CRISPR-Based Therapeutics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of CRISPR-Based Therapeutics include Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific and Horizon Discovery Group, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CRISPR-Based Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CRISPR-Based Therapeutics by region & country, by Type, and by Application.
The CRISPR-Based Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CRISPR-Based Therapeutics.
麻豆原创 Segmentation
By Company
Caribou Biosciences
Addgene
CRISPR THERAPEUTICS
Merck KGaA
Mirus Bio LLC
Editas Medicine
Takara Bio USA
Thermo Fisher Scientific
Horizon Discovery Group
Intellia Therapeutics
GE Healthcare Dharmacon
Segment by Type:
Genome Editing
Genetic Engineering
gRNA Database/Gene Librar
CRISPR Plasmid
Human Stem Cells
Genetically Modified Organisms/Crops
Cell Line Engineering
Segment by Application
Biotechnology Companies
Pharmaceutical Companies
Academic Institutes
Research and Development Institutes
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CRISPR-Based Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CRISPR-Based Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CRISPR-Based Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 CRISPR-Based Therapeutics Product Introduction
1.2 Global CRISPR-Based Therapeutics 麻豆原创 Size Forecast
1.3 CRISPR-Based Therapeutics 麻豆原创 Trends & Drivers
1.3.1 CRISPR-Based Therapeutics Industry Trends
1.3.2 CRISPR-Based Therapeutics 麻豆原创 Drivers & Opportunity
1.3.3 CRISPR-Based Therapeutics 麻豆原创 Challenges
1.3.4 CRISPR-Based Therapeutics 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CRISPR-Based Therapeutics Players Revenue Ranking (2023)
2.2 Global CRISPR-Based Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies CRISPR-Based Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies CRISPR-Based Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of CRISPR-Based Therapeutics
2.6 CRISPR-Based Therapeutics 麻豆原创 Competitive Analysis
2.6.1 CRISPR-Based Therapeutics 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by CRISPR-Based Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CRISPR-Based Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Genome Editing
3.1.2 Genetic Engineering
3.1.3 gRNA Database/Gene Librar
3.1.4 CRISPR Plasmid
3.1.5 Human Stem Cells
3.1.6 Genetically Modified Organisms/Crops
3.1.7 Cell Line Engineering
3.2 Global CRISPR-Based Therapeutics Sales Value by Type
3.2.1 Global CRISPR-Based Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CRISPR-Based Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global CRISPR-Based Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Biotechnology Companies
4.1.2 Pharmaceutical Companies
4.1.3 Academic Institutes
4.1.4 Research and Development Institutes
4.2 Global CRISPR-Based Therapeutics Sales Value by Application
4.2.1 Global CRISPR-Based Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CRISPR-Based Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global CRISPR-Based Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global CRISPR-Based Therapeutics Sales Value by Region
5.1.1 Global CRISPR-Based Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CRISPR-Based Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global CRISPR-Based Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global CRISPR-Based Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America CRISPR-Based Therapeutics Sales Value, 2019-2030
5.2.2 North America CRISPR-Based Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe CRISPR-Based Therapeutics Sales Value, 2019-2030
5.3.2 Europe CRISPR-Based Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific CRISPR-Based Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific CRISPR-Based Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America CRISPR-Based Therapeutics Sales Value, 2019-2030
5.5.2 South America CRISPR-Based Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa CRISPR-Based Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa CRISPR-Based Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CRISPR-Based Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CRISPR-Based Therapeutics Sales Value
6.3 United States
6.3.1 United States CRISPR-Based Therapeutics Sales Value, 2019-2030
6.3.2 United States CRISPR-Based Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CRISPR-Based Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CRISPR-Based Therapeutics Sales Value, 2019-2030
6.4.2 Europe CRISPR-Based Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CRISPR-Based Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CRISPR-Based Therapeutics Sales Value, 2019-2030
6.5.2 China CRISPR-Based Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China CRISPR-Based Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CRISPR-Based Therapeutics Sales Value, 2019-2030
6.6.2 Japan CRISPR-Based Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CRISPR-Based Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CRISPR-Based Therapeutics Sales Value, 2019-2030
6.7.2 South Korea CRISPR-Based Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CRISPR-Based Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CRISPR-Based Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia CRISPR-Based Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CRISPR-Based Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CRISPR-Based Therapeutics Sales Value, 2019-2030
6.9.2 India CRISPR-Based Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India CRISPR-Based Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Caribou Biosciences
7.1.1 Caribou Biosciences Profile
7.1.2 Caribou Biosciences Main Business
7.1.3 Caribou Biosciences CRISPR-Based Therapeutics Products, Services and Solutions
7.1.4 Caribou Biosciences CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 Caribou Biosciences Recent Developments
7.2 Addgene
7.2.1 Addgene Profile
7.2.2 Addgene Main Business
7.2.3 Addgene CRISPR-Based Therapeutics Products, Services and Solutions
7.2.4 Addgene CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 Addgene Recent Developments
7.3 CRISPR THERAPEUTICS
7.3.1 CRISPR THERAPEUTICS Profile
7.3.2 CRISPR THERAPEUTICS Main Business
7.3.3 CRISPR THERAPEUTICS CRISPR-Based Therapeutics Products, Services and Solutions
7.3.4 CRISPR THERAPEUTICS CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Merck KGaA Recent Developments
7.4 Merck KGaA
7.4.1 Merck KGaA Profile
7.4.2 Merck KGaA Main Business
7.4.3 Merck KGaA CRISPR-Based Therapeutics Products, Services and Solutions
7.4.4 Merck KGaA CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Merck KGaA Recent Developments
7.5 Mirus Bio LLC
7.5.1 Mirus Bio LLC Profile
7.5.2 Mirus Bio LLC Main Business
7.5.3 Mirus Bio LLC CRISPR-Based Therapeutics Products, Services and Solutions
7.5.4 Mirus Bio LLC CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 Mirus Bio LLC Recent Developments
7.6 Editas Medicine
7.6.1 Editas Medicine Profile
7.6.2 Editas Medicine Main Business
7.6.3 Editas Medicine CRISPR-Based Therapeutics Products, Services and Solutions
7.6.4 Editas Medicine CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 Editas Medicine Recent Developments
7.7 Takara Bio USA
7.7.1 Takara Bio USA Profile
7.7.2 Takara Bio USA Main Business
7.7.3 Takara Bio USA CRISPR-Based Therapeutics Products, Services and Solutions
7.7.4 Takara Bio USA CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Takara Bio USA Recent Developments
7.8 Thermo Fisher Scientific
7.8.1 Thermo Fisher Scientific Profile
7.8.2 Thermo Fisher Scientific Main Business
7.8.3 Thermo Fisher Scientific CRISPR-Based Therapeutics Products, Services and Solutions
7.8.4 Thermo Fisher Scientific CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Thermo Fisher Scientific Recent Developments
7.9 Horizon Discovery Group
7.9.1 Horizon Discovery Group Profile
7.9.2 Horizon Discovery Group Main Business
7.9.3 Horizon Discovery Group CRISPR-Based Therapeutics Products, Services and Solutions
7.9.4 Horizon Discovery Group CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 Horizon Discovery Group Recent Developments
7.10 Intellia Therapeutics
7.10.1 Intellia Therapeutics Profile
7.10.2 Intellia Therapeutics Main Business
7.10.3 Intellia Therapeutics CRISPR-Based Therapeutics Products, Services and Solutions
7.10.4 Intellia Therapeutics CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.10.5 Intellia Therapeutics Recent Developments
7.11 GE Healthcare Dharmacon
7.11.1 GE Healthcare Dharmacon Profile
7.11.2 GE Healthcare Dharmacon Main Business
7.11.3 GE Healthcare Dharmacon CRISPR-Based Therapeutics Products, Services and Solutions
7.11.4 GE Healthcare Dharmacon CRISPR-Based Therapeutics Revenue (US$ Million) & (2019-2024)
7.11.5 GE Healthcare Dharmacon Recent Developments
8 Industry Chain Analysis
8.1 CRISPR-Based Therapeutics Industrial Chain
8.2 CRISPR-Based Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CRISPR-Based Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 CRISPR-Based Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Caribou Biosciences
Addgene
CRISPR THERAPEUTICS
Merck KGaA
Mirus Bio LLC
Editas Medicine
Takara Bio USA
Thermo Fisher Scientific
Horizon Discovery Group
Intellia Therapeutics
GE Healthcare Dharmacon

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.